Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Pediatr Hematol Oncol. 2009 Oct;31(10):723-9. doi: 10.1097/MPH.0b013e3181b2598c.

Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

Author information

  • 1Department of Pediatric Oncology, Hospital Sant Joan de Déu, Barcelona, Spain. Jmora@hsjdbcn.org

Abstract

AIM OF THE STUDY:

In this report we describe experience with gemcitabine-docetaxel in pediatric patients with relapsed or refractory sarcomas.

PATIENTS AND METHODS:

Ten relapsed/refractory pediatric sarcoma patients including 6 Ewing sarcoma, 2 synovial sarcoma, 1 osteosarcoma, and 1 undifferentiated sarcoma, were treated prospectively, in an outpatient setting, with gemcitabine 1000 mg/m over 90 minutes on day 1 and 8, and docetaxel 100 mg/m over 2 to 4 hours on day 8 of a 21-day cycle, as an investigational rescue therapy.

RESULTS:

The patients (ages 4 to 18) received a total of 70 cycles of therapy (median 6 cycles; range: 4 to 10 y). All symptomatic patients responded clinically to the new regimen. By Response Evaluation Criteria in Solid Tumors criteria, 4 (40%) patients had a complete response (CR), 1 (10%) had a partial response (PR), 3 (30%) had stable disease (SD), and 2 (20%) had a progressive disease (PD), which provides an objective response rate (CR+PR) of 50%. Median duration of response (CR+PR+SD) was 10 months (range: 6 to 32+ mo). Five out of the 10 patients (50%) are alive, with a median follow-up of 48 months from diagnosis. Mild toxicities (no grades 3 to 4) were encountered and managed in the ambulatory setting.

CONCLUSIONS:

The gemcitabine-docetaxel regimen demonstrated antitumor activity against advanced pediatric (mainly Ewing) sarcomas, allowing for good quality of life. Evaluation in a large, formal phase 2 trials for Ewing patients is ongoing.

PMID:
19727011
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk